PF-622
Piperazine urea that inhibits FAAH by covalent modification of the active-site serine, completely selective among the mammalian serine hydrolases tested.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₁H₂₂N₄O
CID 11515763
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 346.40 g/mol
Updated on
In plain terms
PF-622 blocks the enzyme that destroys anandamide, one of the cannabinoids the body makes. Its interest is being very precise: in the tests, it touches no other enzyme of the same type. It has remained a laboratory tool; no study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to PF-622: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PF-622.
FAAHFAAH found in 7 regions of the body
- CortexpresentCortical pyramidal neurons1
- Basal gangliapresentStriatal neurons1
- HypothalamuspresentPresent in hypothalamic nuclei1
- CerebellumpresentPurkinje cells and cerebellar layers1
- BrainstempresentInferior olivary nuclei1
- Adipose tissuepresentExpressed in mature adipocytes2
- BonepresentPresent on osteoclasts3
Map sources
- Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res, 2002 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- FAAHInhibitorno measured value cited
Time-dependent covalent inhibition (modification of the active-site nucleophilic serine); complete selectivity among mammalian serine hydrolases in activity-based probe profiling; no numerical value in the abstract of Ahn et al. 2007; other publications: IC50 of 19 to 991 nM depending on the assay (ChEMBL)
Pharmacology
PF-622 was published in 2007 with PF-750 as the lead of a new mechanistic class of FAAH inhibitors. The paper by Ahn and colleagues describes piperidine and piperazine ureas that are more potent in vitro than earlier classes, and whose inhibition of FAAH, unexpectedly given the chemical stability of the urea group, is time-dependent and goes through covalent modification of the active-site serine nucleophile. Activity-based proteomic profiling shows them to be completely selective for FAAH among other mammalian serine hydrolases, a specificity the authors link to FAAH's special ability to hydrolyse C(O)-N bonds, where most serine hydrolases cut only esters or thioesters. The authors see in them a privileged scaffold for FAAH inhibitors combining potency and selectivity. For class context, a phase 1 study of another FAAH inhibitor, BIA 10-2474, led to the death of one volunteer and neurological symptoms in four others; the cause is unknown and a hypothesis of inhibition of several lipases not targeted by a highly selective FAAH inhibitor has been put forward (van Esbroeck et al. 2017). No study in whole animals or in humans was found for PF-622.
Key sources.
- Ahn K et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry, 2007 (new tab)PMID 17949010
- van Esbroeck ACM et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science, 2017 (new tab)PMID 28596366
- PubChem, PF-622, CID 11515763 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence. It is known as a pharmacology reagent, a demonstration tool for a new mechanistic class; no clinical development was found in the sources consulted.
Origin
Research tool
No biological pathway: PF-622 is a synthetic compound of the piperazine urea class, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: PF-622 is not on the ANSM consolidated list of narcotics (updated 16/02/2026) and this piperazine urea falls within none of the generic families of that list. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
No dedicated article.
References
- Ahn K et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry, 2007 (new tab)PMID 17949010
- van Esbroeck ACM et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science, 2017 (new tab)PMID 28596366
- PubChem, PF-622, CID 11515763 (identifiers and properties) (new tab)
Identifiers
Names
- IUPAC name
- N-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide
- Other names
- PF 622 · PF622
Identifiers
- Formula
- C₂₁H₂₂N₄O
- PubChem CID
- 11515763(new tab)
- InChIKey
- SNTCRRMCALVGNL-UHFFFAOYSA-N
- SMILES
- C1CN(CCN1CC2=
NC3= CC= CC= C3C= C2) C(= O) NC4= CC= CC= C4
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.